BACKGROUND: The objective was to investigate the impact of adjuvant hepatic arterial infusion pump (HAIP) chemotherapy on the rates and patterns of recurrence and survival in patients with resected colorectal liver metastases (CRLM). METHODS: Recurrence rates, patterns, and survival were compared between patients treated with and without adjuvant HAIP using competing risk analyses. RESULTS: 2128 patients were included, of which 601 patients (28.2%) received adjuvant HAIP and systemic chemotherapy (HAIP + SYS). The overall recurrence rate was similar with HAIP + SYS or SYS (63.5% versus 64.2%,p = 0.74). The 5-year cumulative incidence of initial intrahepatic recurrences was lower with HAIP + SYS (22.9% versus 38.4%,p < 0.001). The 5-year cumulative incidence of initial extrahepatic recurrences was higher with HAIP + SYS (48.5% versus 40.3%,p = 0.005), because patients remained at risk for extrahepatic recurrence in the absence of intrahepatic recurrence, which was largely attributable to more pulmonary recurrences with HAIP + SYS (33.6% versus 23.7%,p < 0.001). HAIP was an independent prognostic factor for DFS (adjusted HR 0.69, 95% CI 0.60-0.79, p < 0.001), and OS (adjusted HR 0.67, 95% CI 0.57-0.78,p < 0.001). CONCLUSION: Adjuvant HAIP chemotherapy is associated with lower intrahepatic recurrence rates and better DFS and OS after resection of CRLM.
BACKGROUND: The objective was to investigate the impact of adjuvant hepatic arterial infusion pump (HAIP) chemotherapy on the rates and patterns of recurrence and survival in patients with resected colorectal liver metastases (CRLM). METHODS: Recurrence rates, patterns, and survival were compared between patients treated with and without adjuvant HAIP using competing risk analyses. RESULTS: 2128 patients were included, of which 601 patients (28.2%) received adjuvant HAIP and systemic chemotherapy (HAIP + SYS). The overall recurrence rate was similar with HAIP + SYS or SYS (63.5% versus 64.2%,p = 0.74). The 5-year cumulative incidence of initial intrahepatic recurrences was lower with HAIP + SYS (22.9% versus 38.4%,p < 0.001). The 5-year cumulative incidence of initial extrahepatic recurrences was higher with HAIP + SYS (48.5% versus 40.3%,p = 0.005), because patients remained at risk for extrahepatic recurrence in the absence of intrahepatic recurrence, which was largely attributable to more pulmonary recurrences with HAIP + SYS (33.6% versus 23.7%,p < 0.001). HAIP was an independent prognostic factor for DFS (adjusted HR 0.69, 95% CI 0.60-0.79, p < 0.001), and OS (adjusted HR 0.67, 95% CI 0.57-0.78,p < 0.001). CONCLUSION: Adjuvant HAIP chemotherapy is associated with lower intrahepatic recurrence rates and better DFS and OS after resection of CRLM.
Authors: Halfdan Sorbye; Murielle Mauer; Thomas Gruenberger; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Eric Van Cutsem; Werner Scheithauer; Manfred P Lutz; Bernard Nordlinger Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: N Kemeny; Y Huang; A M Cohen; W Shi; J A Conti; M F Brennan; J R Bertino; A D Turnbull; D Sullivan; J Stockman; L H Blumgart; Y Fong Journal: N Engl J Med Date: 1999-12-30 Impact factor: 91.245
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: Sepideh Gholami; Nancy E Kemeny; Taryn M Boucher; Mithat Gönen; Andrea Cercek; T Peter Kingham; Vinod Balachandran; Peter Allen; Ronald DeMatteo; Jeffrey Drebin; William Jarnagin; Michael D'Angelica Journal: Ann Surg Date: 2020-08 Impact factor: 12.969
Authors: Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs Journal: Sci Transl Med Date: 2016-07-06 Impact factor: 17.956
Authors: Nancy E Kemeny; Joanne F Chou; Taryn M Boucher; Marinela Capanu; Ronald P DeMatteo; William R Jarnagin; Peter J Allen; Yuman C Fong; Andrea Cercek; Michael I D'Angelica Journal: J Surg Oncol Date: 2016-02-02 Impact factor: 3.454
Authors: F E Buisman; M Y V Homs; D J Grünhagen; W F Filipe; R J Bennink; M G H Besselink; I H M Borel Rinkes; R C G Bruijnen; A Cercek; M I D'Angelica; O M van Delden; M L Donswijk; L van Doorn; P G Doornebosch; J Emmering; J I Erdmann; N S IJzerman; C Grootscholten; J Hagendoorn; N E Kemeny; T P Kingham; E G Klompenhouwer; N F M Kok; S Koolen; K F D Kuhlmann; M C Kuiper; M G E Lam; R H J Mathijssen; A Moelker; E Oomen-de Hoop; C J A Punt; W W Te Riele; J M L Roodhart; R J Swijnenburg; W Prevoo; P J Tanis; M Vermaas; M W J Versleijen; F P Veuger; M J Weterman; C Verhoef; B Groot Koerkamp Journal: BMC Cancer Date: 2019-04-05 Impact factor: 4.430
Authors: Lily V Saadat; Thomas Boerner; Debra A Goldman; Mithat Gonen; Timothy L Frankel; Efsevia Vakiani; T Peter Kingham; William R Jarnagin; Alice C Wei; Kevin C Soares; David B Solit; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2020-07-18 Impact factor: 5.344